Evidence map›Paper›PMID 29387008›Full record

ArticleFrontiers in pharmacology2017

Rikkunshito for Preventing Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: Results from 2 Prospective, Randomized Phase 2 Trials.

Toshiyuki Harada, Toraji Amano, Tomoo Ikari, Kei Takamura, Takahiro Ogi, Toshiaki Fujikane, Yuka Fujita, Kageaki Taima, Hisashi Tanaka, Takaaki Sasaki and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Toshiyuki HaradaCenter for Respiratory Diseases, JCHO Hokkaido Hospital, Sapporo, Japan.
Toraji AmanoClinical Research and Medical Innovation Center, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Tomoo IkariCenter for Respiratory Diseases, JCHO Hokkaido Hospital, Sapporo, Japan.
Kei TakamuraDepartment of Respiratory Medicine, Obihiro-Kosei General Hospital, Obihiro, Japan.
Takahiro OgiDepartment of Respiratory Medicine, Obihiro-Kosei General Hospital, Obihiro, Japan.
Toshiaki FujikaneDepartment of Respiratory Medicine, National Hospital Organization Asahikawa Medical Center, Asahikawa, Japan.
Yuka FujitaDepartment of Respiratory Medicine, National Hospital Organization Asahikawa Medical Center, Asahikawa, Japan.
Kageaki TaimaDepartment of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Hisashi TanakaDepartment of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Takaaki SasakiRespiratory Center, Asahikawa Medical University Hospital, Asahikawa, Japan.
Shunsuke OkumuraRespiratory Center, Asahikawa Medical University Hospital, Asahikawa, Japan.
Shunichi SugawaraDepartment of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Hiroshi YokouchiDepartment of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
Noriyuki YamadaDepartment of Respiratory Medicine, Iwamizawa Municipal General Hospital, Iwamizawa, Japan.
Naoto MorikawaDivision of Pulmonary Medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan.
Hirotoshi Dosaka-AkitaDepartment of Medical Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Hiroshi IsobeRespiratory Center, KKR Sapporo Medical Center, Sapporo, Japan.
Masaharu NishimuraFirst Department of Medicine, Hokkaido University Hospital, Sapporo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The herbal medicine rikkunshito has the potential to improve chemotherapy-induced nausea and vomiting (CINV) by stimulating ghrelin secretion. We aimed to evaluate the efficacy and safety of rikkunshito in preventing CINV for patients with lung cancer. Two separate prospective, randomized, phase II parallel design studies were conducted in patients with lung cancer. Fifty-eight and sixty-two patients scheduled to receive highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC), respectively, were randomized 1:1 to receive either standard antiemetic therapy in accordance with international guidelines (S group) or standard antiemetic therapy plus oral rikkunshito (R group). The primary endpoint was overall complete response (CR)-that is, no emesis and rescue medication in the first 120 h post-chemotherapy. Secondary endpoints included CR in the acute (0-24 h) and delayed (>24-120 h) phases and safety. Fifty-seven patients (S group, 28; R group, 29) receiving HEC and sixty-two patients (S group, 30; R group, 32) receiving MEC with comparable characteristics were evaluated. The CR rates were similar across the S and R groups for the HEC study in the overall (67.9% vs. 62.1%), acute (96.4% vs. 89.6%), and delayed (67.9% vs. 62.1%) phases, respectively, and for the MEC study in the overall (83.3% vs. 84.4%), acute (100% vs. 100%), and delayed (83.3% vs. 84.4%) phases, respectively. No severe adverse events were observed. Although rikkunshito was well tolerated, it did not demonstrate an additional preventative effect against CINV in lung cancer patients receiving HEC or MEC.

Indexed as

chemotherapyherbal medicinelung cancernauseavomiting

Identifiers

PMID29387008
PMCPMC5776023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.